Join
Live feed
·
PRReleasevia Quantisnow
Regeneron Pharmaceuticals Inc. logo

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

ByQuantisnow·Wall Street's wire, on your screen.
REGN· Regeneron Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REGN (Regeneron Pharmaceuticals Inc.) and more on Quantisnow.